Viewing Study NCT05432193

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 1:17 AM

Ignite Modification Date: 2025-12-27 @ 2:07 AM

Study NCT ID: NCT05432193

Status: TERMINATED

Last Update Posted: 2025-06-25

First Post: 2022-06-08

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module